Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 3/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334434 | 1.00 | TSHR (0.58) | TSHRALDH1A1DNM1FAAHTRPV1 | |
| SCHEMBL7282265 | 1.00 | TSHR (0.58) | TSHRALDH1A1DNM1FAAHTRPV1 | |
| SCHEMBL7294715 | 1.00 | TSHR (0.58) | TSHRALDH1A1DNM1FAAHTRPV1 | |
| SCHEMBL7284860 | 1.00 | TSHR (0.58) | TSHRALDH1A1DNM1FAAHTRPV1 | |
| SCHEMBL7291004 | 1.00 | TSHR (0.58) | TSHRALDH1A1DNM1FAAHTRPV1 | |
| SCHEMBL18807792 | 1.00 | TSHR (0.58) | TSHRALDH1A1DNM1FAAHTRPV1 | |
| SCHEMBL7285272 | 1.00 | TSHR (0.58) | TSHRALDH1A1DNM1FAAHTRPV1 | |
| Iodide SCHEMBL25402951 | 0.97 | TSHR (0.55) | TSHRALDH1A1DNM1FAAHTRPV1 | |
| SCHEMBL5226044 | 0.97 | TSHR (0.55) | TSHRALDH1A1DNM1FAAHTRPV1 | |
| Bromide SCHEMBL25406243 | 0.97 | TSHR (0.55) | TSHRALDH1A1DNM1FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801850-B2 | Antibacterial agent | OSAKA UNIVERSITY (JP) | 2017-10-31 | — | — | US | claimed |
| US-20150111961-A1 | MEMBRANE FUSION INHIBITOR | PROTECTEA, LTD. (JP) | 2015-04-23 | — | — | US | claimed |
| EP-2460405-A1 | ANTIBACTERIAL AGENT | Osaka University (JP) | 2012-06-06 | — | — | EP | claimed |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2012-05-31 | — | — | US | claimed |
| CN-102480952-A | Antibacterial agent | UNIV OSAKA | 2012-05-30 | — | — | CN | claimed |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | KAIHATSU, Kunihiro (JP) | 2011-01-06 | — | — | US | claimed |
| CN-101932320-A | Membrane fusion inhibitor | KUNIHIRO KAIHATSU | 2010-12-29 | — | — | CN | claimed |
| US-9901565-B2 | Membrane fusion inhibitor | PROTECTEA, LTD. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-9801850-B2 | Antibacterial agent | OSAKA UNIVERSITY (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20150111961-A1 | MEMBRANE FUSION INHIBITOR | PROTECTEA, LTD. (JP) | 2015-04-23 | — | — | US | disclosed |
| EP-2460405-B1 | EPIGALLOCATECHIN GALLATE DERIVATIVE AS ANTIBACTERIAL AGENT | UNIV OSAKA (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-8952055-B2 | Membrane fusion inhibitor | PROTECTEA, LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-102480952-B | Antibacterial agent | UNIV OSAKA NAT UNIV CORP | 2015-01-21 | — | — | CN | disclosed |
| CN-101932320-B | Membrane fusion inhibitor | KAIHATSU KUNIHIRO | 2014-06-18 | — | — | CN | disclosed |
| EP-2460405-A1 | ANTIBACTERIAL AGENT | Osaka University (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2012-05-31 | — | — | US | disclosed |
| CN-102480952-A | Antibacterial agent | UNIV OSAKA | 2012-05-30 | — | — | CN | disclosed |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | KAIHATSU, Kunihiro (JP) | 2011-01-06 | — | — | US | disclosed |
| CN-101932320-A | Membrane fusion inhibitor | KUNIHIRO KAIHATSU | 2010-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136049-A1 | ANTIBACTERIAL AGENT | TEAD4, ELOVL6, TEAD1 | TSHR 2877/4885ALDH1A1 677/4885DNM1 812/4885 |
| US-20150111961-A1 | MEMBRANE FUSION INHIBITOR | FLOT1, NSF, VAMP7 | TSHR 2134/4885ALDH1A1 2332/4885DNM1 20/4885 |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | FLOT1, NSF, VAMP7 | TSHR 2134/4885ALDH1A1 2332/4885DNM1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.